16 results about "Megakaryocytic cell" patented technology

The present disclosure relates to the field of biological medicine, and provides a use of a dihydroorotate dehydrogenase inhibitor in the preparation of megakaryocytes, wherein the dihydroorotate dehydrogenase inhibitor is a compound represented by formula I, formula II or formula III, or a pharmaceutically acceptable salt of the compound. The dihydroorotate dehydrogenase inhibitor in the technical solution of the present disclosure can promote the differentiation of hematopoietic stem / progenitor cells into megakaryocytes and platelets, and increase the platelet production by about 2 times, thereby providing a promising strategy for the production of megakaryocytes and platelets in vivo and in vitro.

GABRR1 is shown to be expressed on subsets of hematopoietic stem cells (HSCs) and megakaryocyte progenitors (MkPs). Inhibition of GABRR1 inhibits MkP differentiation and reduction of platelet numbers in blood. Overexpression of GABRR1 or treatment with agonists significantly promotes MkP generation and growth of megakaryocytes.

The present application provides the use of leukotrienes in inducing stem cells to differentiate into hematopoietic stem / progenitor cells and the application thereof. According to specific embodiments of the present application, the addition of appropriate amounts of leukotrienes during the process of inducing stem cells to differentiate into hematopoietic stem / progenitor cells can significantly improve the differentiation efficiency of the stem cells into hematopoietic stem / progenitor cells, and significantly increase the number of erythroid cells, megakaryocytic cells, granulocytic cells and mononuclear cells obtained after the differentiation of the stem cells through hematopoietic stem / progenitor cells.

The invention belongs to the field of platelet differentiation, and particularly relates to application of an adenosine A2a receptor stimulant in induced differentiation of platelets. The invention provides an application of an adenosine A2a receptor agonist in inducing differentiation of hematopoietic stem progenitor cells and / or megakaryocyte progenitor cells to generate platelets. The adenosine A2a receptor agonist contains Redelbrusone; in addition, the invention further provides a culture medium containing the adenosine A2a receptor stimulant and application of the culture medium in preparation of platelets through in-vitro differentiation, and provides an in-vitro differentiation method of the platelets, and the in-vitro differentiation method of the platelets improves the yield of the platelets by nearly one time.

This application discloses a method, system, device, storage medium, and product for detecting megakaryocytes, comprising: acquiring pathological slide images and preprocessing the pathological slides, wherein the preprocessing further includes generating small-sized pathological slides based on the pathological slides; inputting the preprocessed pathological slides into a pre-trained segmentation model to output megakaryocyte information and location information; stitching the small pathological slides to generate a high-resolution pathological slide image; inputting the high-resolution pathological slide image into a classification model to output megakaryocyte classification results; acquiring megakaryocyte clustering information based on the high-resolution pathological slide image, and generating medical information based on the megakaryocyte information and location information, the megakaryocyte classification results, and the megakaryocyte clustering information. This method solves the problems of low accuracy and long reading time in manual review of megakaryocyte slides.

Methods for producing megakaryoctyres and platelets derived from inducible pluripotent stem cells are provided. Such megakaryocytes or platelets can be genetically modified to comprise a nucleic acid molecule encoding a therapeutic agent. The present disclosure further provides methods and compositions for loading a platelet or a megakaryocyte with a therapeutic agent and for genetically modifying a platelet or a megakaryocyte to express an agent.

Methods for producing megakaryoctyres and platelets derived from inducible pluripotent stem cells and comprising a therapeutic agent are provided. The present disclosure further provides methods and compositions for loading a platelet or a megakaryocyte with a therapeutic agent and for genetically modifying a platelet or a megakaryocyte to express an agent.

The invention provides an anti-human CD42b antibody and application thereof. The antibody comprises a heavy chain variable region and a light chain variable region, the CDR1, the CDR2 and the CDR3 of the heavy chain variable region are amino acid sequences as shown in SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3 respectively; the CDR1, the CDR2 and the CDR3 of the light chain variable region are amino acid sequences as shown in SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6 respectively. The anti-human CD42b antibody provided by the invention provides an anti-human CD42b monoclonal antibody light chain variable region gene and a heavy chain variable region gene, and a hybridoma cell strain capable of generating a CD42b specific antibody, and can be used for detection of human and megakaryocyte / platelets.

The present application relates to a method for improving the quality of platelets produced in vitro. Specifically, the present inventors provide a platelet culture medium for in vitro culture, which can significantly improve the yield and quality of platelets cultured in vitro by optimizing the ingredients and adding new ingredients. Specifically, the viability of platelets obtained by culturing megakaryocytes in the culture medium of the present application and the proportion of CD42b+ cells are significantly increased, and the number of platelets produced by a single megakaryocyte is also significantly increased. The present application improves the problems of imperfect platelet function and unstable quality in existing in vitro platelet production technology, provides a stable platelet source for clinical transfusion, and has a wide application prospect.

The present invention provides a method for producing human immortalized megakaryocytes and / or human immortalized megakaryocyte progenitor cells and / or human megakaryocyte cell lines (102) from adult CD34 + HSPC (100) capable of maturation into functional megakaryocytes (103) producing functional platelets (104), said method comprising at least the steps of: producing functional platelets (104) by transduction, in particular lentiviral (LV) transduction; an expression cassette comprising at least one gene is introduced into the CD34 + HSPC (100) to effectuate forced expression of the at least one gene wherein the transduced CD34 + HSPC (100) is configured to express at least one gene from the HOXL subclass of the ANTP homologous cassette family and / or the TALE homologous cassette family upon activator-induced expression, and constitutively expressing at least one anti-apoptotic gene from the BCL2 family wherein the transduced CD34 + HSPC (100) is immortalized by expression of the at least one gene from the ANTP homologous cassette family and / or the HOXL subclass of the TALE homologous cassette family, preferably wherein the at least one gene from the HOXL subclass comprises a combination of one of the HOXB8, HOXA7, HOXA10 or HOXB4 genes and at least one of the MEIS1, MEIS2, MEIS3, PBX1, PBX2, PBX3 and / or PBX4 genes, and the at least one anti-apoptosis gene from the BCL2 family comprises BCL2L1 or BCL2L2. The invention further provides a method of producing functional platelets by using the immortalized megakaryocytes and / or immortalized megakaryocyte progenitor cells and / or immortalized megakaryocyte cell lines obtained by the above method. Further, the present invention provides a pharmaceutical composition comprising functional platelets obtained by the above method and its therapeutic use.

The invention provides a combination capable of efficiently inducing differentiation of hematopoietic stem / progenitor cells to megakaryocyte lineage cells. The combination comprises three components: a first component, a second component and a third component, wherein the first component is an HSE7 gene or protein, mRNA of HSE7, an HSE7 expression cassette or an HSE7 accelerant; the second component is a histone deacetylase inhibitor; and the third component is a gamma-aminobutyric acid agonist. Also provided is a method for efficiently inducing differentiation of hematopoietic stem / progenitor cells into meganuclear lineage cells, comprising overexpressing HSE7, inhibiting HDAC expression and / or activity, and administering a GABA agonist.

The invention relates to the technical field of aerospace, in particular to a method for overcoming the influence of microgravity on fetal development in a space extrauterine mode through a motor West-Cherry-Pu, a system is intelligently controlled through a nine-order magic-square calculation model, automatic implementation of research is achieved, proliferation and differentiation are carried out on microgravity inhibition in-vitro cultured megakaryocytes, and the effect of the microgravity inhibition in-vitro cultured megakaryocytes on fetal development is achieved. The expression of gravity-sensitive molecules under a microgravity condition is changed and cell proliferation and differentiation are changed, so that down-regulation of transcription factors RUNX-1 and Ets-1 leads to c-mpl gene transcription activation disorder and down-regulation of c-mpl expression level, and a c-mpl mediated signal channel is partially closed to cause a related mechanism of inhibiting proliferation and differentiation of megakaryocyte in a microgravity environment. And a better solution and an optimal effect of overcoming the influence of microgravity on fetal development outside the space uterus are achieved.

The present invention provides engineered platelets having a chimeric platelet receptor (CPR) with desired target specificity. Furthermore, the engineered platelets may contain cargo that can be released upon platelet activation. In addition, the platelets can be generated in vitro from megakaryocytes engineered to produce non-thrombotic platelets. [Solution] To provide an engineered megakaryocyte or precursor capable of reducing thrombogenic ability and / or producing platelets with reduced thrombogenic ability, comprising the disruption or deletion of at least one gene encoding a protein involved in the recognition of a primary stimulus for thrombosis, one gene encoding a protein involved in the recognition of a secondary mediator for thrombosis, and one gene encoding a protein involved in the release of a secondary mediator for thrombosis.

Cell-derived composition having physiological activity SOLUTION: The composition of the present invention contains a processed product of megakaryocytes or a culture thereof.SELECTED DRAWING: None

The present disclosure, in various aspects and embodiments, provides methods for generating hematopoietic lineages for cell therapy, including erythroid progenitor cells, progenitor erythroblasts, granulocyte-macrophage progenitor cells (GMPs), and megakaryocyte erythroid progenitor cells (MEPs), and erythroid cells. In various embodiments, the invention provides for efficient ex vivo processes for developing such hematopoietic lineages, including but not limited to progenitor erythroblast cells and erythroblast cell lineages, from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and / or more closely resemble the corresponding lineage isolated from peripheral blood or bone marrow. The present invention also provides isolated cells and cell compositions produced by the methods disclosed herein, as well as methods for cell therapy.